Comparison of Asymptomatic Carotid Atherosclerosis Between Frequent and Infrequent Blood Donors
NCT ID: NCT00001589
Last Updated: 2008-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
1997-04-30
2002-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Carotid Atherosclerosis Follow-up Study
NCT00005189
Risk Factor Analysis for Coronary Atherosclerosis Measured by MDCT
NCT01589224
Detection of Subclinical Atherosclerosis in Asymptomatic Individuals
NCT00862056
The Association Between Systemic Microvascular Endothelial Function and Coronary Physiology Indexes
NCT05864729
Effect of Drug Therapy on Reinfarction Risk in Women
NCT00005389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Standard eligibility criteria for blood donation, per guidelines established by the Food and Drug Administration and the American Association of Blood Banks.
Ability to provide consent after full information is provided.
Exclusion Criteria
Patients with clinically significant dementia or psychiatric disturbances, including alcohol and substance abuse.
Presence of the following American Heart Association cardiovascular risks: diabetes mellitus, hypertension (systolic greater than 140 mmHg, diastolic greater than 90 mmHg), smoking (greater than 10 cigarettes/day), high density lipoprotein cholesterol less than 35 mg/dL, hyperlipidemia (total cholesterol greater than 240 mg/dL), family history of premature coronary heart disease.
Anticoagulant, thrombolytic, hemorrheologic and/or antiplatelet agents (within the last 10 days).
Any other condition or therapy which in the opinion of the investigators may pose a risk to the patient or confound the results of the study.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health Clinical Center (CC)
NIH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fuster V. Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994 Oct;90(4):2126-46. doi: 10.1161/01.cir.90.4.2126.
Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994 Jun 15;120(12):1012-25. doi: 10.7326/0003-4819-120-12-199406150-00008.
Kannel WB. Clinical misconceptions dispelled by epidemiological research. Circulation. 1995 Dec 1;92(11):3350-60. doi: 10.1161/01.cir.92.11.3350.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
97-CC-0113
Identifier Type: -
Identifier Source: secondary_id
970113
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.